Breaking News from ADA 2021
This page was last updated at 7:35 am PT June 29, 2021.
Editor’s Note: This article was updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Coverage of the ADA Scientific Sessions is brought to you by the ADA x BT1 Collab.
Tuesday, June 29, 2021
- Walmart announced the launch of the first-ever private brand analog insulin. The new private label ReliOn NovoLog Insulin (insulin aspart) injection, manufactured by Novo Nordisk, is available in Walmart pharmacies this week, and Sam’s Club pharmacies in mid-July across the United States. The new offering includes insulin vials at $72.88 and FlexPen packages at $85.88, saving customers between 58 percent to 75 percent off the cash price of branded analog insulin products.
- Data from the wide-scale, global SURPASS Clinical trial for the novel dual GIP/GLP-1, Tirzepatide, showed significant reductions in A1C and body weight for people with type 2 diabetes when compared to several different treatments including GLP-1, basal insulin and metformin. While the news reported on Saturday centered on the first phase, SURPASS-1, today’s news encompasses all current five phases of the trial. Notable changes in A1c for some of the trials were: SURPASS-1: When compared to placebo, 92 percent of patients achieved an A1C <7% and 52% achieved an A1C <5.7, the level for people without diabetes.
- SURPASS-2: When compared to semaglutide, 92 percent of patients achieved an A1C <7%, and 51 percent achieved an A1C <5.7, the level for people without diabetes.
- SURPASS-3: When compared to insulin degludec, 93 percent of patients achieved an A1C <7%, and 48 percent achieved an A1C <5.7, the level for people without diabetes.
- SURPASS-5: When compared to insulin glargine, 97 percent of patients achieved an A1C <7%, and 62 percent achieved an A1C <5.7, the level for people without diabetes.
Monday, June 28, 2021
- Medtronic announced key clinical data from #ADA2021. Presentations illustrated increases in Time in Range when using an InPen smart insulin pen, safety of an extended-wear infusion set that lasts up to seven days, and patient satisfaction with the longer-wear infusion set.
- Data from a large-scale international AMPLITUDE O trial showed that use of the once-weekly injectable efpeglenatide, a GLP-1, significantly reduces the first occurrence of adverse cardiovascular events such as heart attack, stroke, or death and a decrease in the progression of kidney disease in patients with type 2 diabetes. The two-year trial was conducted in eight countries and had over 4,000 participants. Compared to those who took the placebo, patients who took the GLP-1 had a 27 percent lower risk of a heart attack, stroke, or cardiovascular death. In regards to kidney disease, they displayed a 32 percent lower risk of developing it. There were no serious side effects reported.
- New research from the Centers for Disease Control and Prevention (CDC) revealed income-related inequalities in diabetes have widened over the past decade, from 2001 to 2018. Through that time period, diabetes was more prevalent in low-income communities, but income inequalities narrowed between 2001-2011 and then widened in 2011-2018. Compared to people in high-income households, the prevalence of diabetes increased by 40 percent, 74.1 percent and 100.4 percent for those from middle-income, near-poor and poor, respectively.
Sunday, June 27, 2021
- Results from DARE-19, the first large randomized clinical trial to assess (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19 showed that Dapagliflozin is well tolerated.
- In an early morning session at ADA titled “Who Should Loop?”, providers and patients gave perspectives on the current state of DIY Looping systems in 2021 and discussed the pros and cons of the various systems.
- A discussion about the progression of type 2 diabetes in children/youth (aged 10-19) showed that compared to adults: diabetes in children is more aggressive, beta-cell function decreases faster even with medications and complications such as retinopathy and cardiovascular issues are accelerated and usually found at diagnosis. The discussion also discussed new and ongoing trials to increase the chances of approval of the use of type 2 diabetes, typically used for adults, for children.
Saturday, June 26, 2021
- Data from a study of preschool-age (2-5.9 years old) children using the Omnipod 5 Hybrid Closed Loop System was presented today at ADA. The system led to a reduction in HbA1C, improved Time in Range and no significant increase in hypoglycemia.
- The presentation “Current Role of Pancreas Transplantation in the Treatment of Diabetes” discussed transplants in both type 1 and type 2 diabetes. Originally thought of as treatment for type 1 diabetes in patients with severe hypoglycemia unawareness and other comorbidities, 20 percent of transplants in the US are in those with type 2 diabetes.
- Prominent diabetes researchers Anne Peters, M.D., and Kasia Lipska, MD, MHS, debated the use of digital coaching for patients with type 2 diabetes. The debate’s central question posed: are they worth the cost? Peters, a Beyond Type 1 Leadership Council Member, took the position of “yes” while Lipska took the opposite position. The debate was listed as one of the highlighted sessions for this year’s conference.
- Data from the SURPASS-1 clinical trial presented by Lilly Diabetes shows Tirzepatide’s superior A1C and reductions in bodyweight in people with type 2 diabetes compared to those who received the placebo. The study, which was recently published in The Lancet, showed the highest dose of Tirzepatide reduced A1C by 2.07 percent and bodyweight by 20.9 lb/9.5 kg (11 percent). The lowest dose of Tirzepatide lowered A1C by 1.87 percent and bodyweight by 15.4 lb/ 7.0 kg (7.9 percent). Tirzepatide—a dual GIP/GLP-1—is a new treatment for type 2 diabetes.
Friday, June 25, 2021
- AstraZeneca presented strong phase 3 results of the GLP-1 Bydureon (once-weekly exenatide) which showed significantly reduced levels of HbA1C in children aged 10-17 with type 2 diabetes. Over the 24 weeks of the trial, those who received the drug had an A1c reduction of 0.36 percent, whereas those who did not saw their A1c increase by 0.49 percent.
- Lilly’s SURPASS-2 results published in The New England Journal of Medicine and presented at ADA showed all three doses tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes.
- ViaCyte announced preliminary clinical data from its stem cell-derived islet cell replacement therapy for patients with type 1 diabetes (T1D). The results showed PEC‑Direct (VC-02) demonstrates effective engraftment and production of C-peptide.
- A new study presented in a late Breaking Poster Session shows that hospitalization rates for new onset pediatric type 2 diabetes doubled during the Covid-19 Pandemic.
Thursday, June 24, 2021
- Zealand Pharma announced that Zegalogue® (dasiglucagon) is commercially available in the U.S. in an auto-injector and prefilled syringe, after receiving FDA approval on March 22, 2021.
- Bigfoot Biomedical announced that its Bigfoot Unity™ Diabetes Management Program is now available to diabetes clinics and endocrinology practices in select markets across the U.S.
- ADA announced that the 81st Scientific Sessions will feature five COVID-19 Symposia, highlighting cutting-edge science and the latest diabetes developments learned during the initial phases of the pandemic. The Symposia will be presented over the course of the annual meeting taking place June 25–29.
For Full ADA 2021 Coverage from Beyond Type 1 CLICK HERE